Starpharma gets US FDA clearance to begin phase 2 bacterial vaginosis study for VivaGel
Monday, July 19, 2010 11:00 IST Melbourne Australia
Starpharma Holdings Limited announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel for the treatment of bacterial vaginosis (BV).
